Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2022-09-09 17:00:00
Oslo, Norway, September 9, 2022 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that its Chief Executive
Officer, Michael Engsig, and Chief Business Officer & Co-founder, Agnete
Fredriksen, will present at the H.C. Wainwright 24th Annual Global Investment
Conference on Tuesday, September 13, 2022 at 11:00 a.m. ET / 5:00 p.m. CET and
are available for 1:1 investor meetings.
The live and archived webcast of the presentation can be accessed in the
Investors section of the Company's website:
www.nykode.com/investors/financial-reports-and-presentations.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer and infectious diseases. Nykode's modular vaccine technology specifically
targets antigens to Antigen Presenting Cells, which are essential for inducing
rapid, strong and long-lasting antigen specific immune responses and eliciting
efficacious clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase II
trial for the treatment of cervical cancer